Subtype
Malignant Retroperitoneal Neoplasm
CI-CAN-00001174Explore in graph →
41 active trials1 approved drugs2 evidence items
- NCIt
- C3537
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001174Explore in graph →
Clinical trials
132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (17)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06900595 | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 18, 2026 |
| clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01659203 | Proton or Photon RT for Retroperitoneal Sarcomas | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | active not recruiting | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03127774 | Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma | active not recruiting | Phase 2 | 30 | Columbia UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06066333 | Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma | recruiting | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04189783 | Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02673333 | Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06006013 | Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer | recruiting | Phase 2 | 21 | Emory UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT05036434 | Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma(ACCOMPLISH) | active not recruiting | Phase 2 | 30 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07085572 | Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer(INTERVAL) | recruiting | Phase 2 | 31 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | recruiting | Phase 2 | 28 | West China HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06587802 | Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma | recruiting | Phase 2 | 18 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05563467 | Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.(PEMBR-01) | recruiting | Phase 2 | 24 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03370718 | Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03612232 | Cabozantinib in Advanced Adrenocortical Carcinoma(CaboACC) | unknown | Phase 2 | 37 | Wuerzburg University HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05913427 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)(PESETA) | recruiting | Phase 2 | 80 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | unknown | Phase 2 | 21 | West China HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT01566123 | Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS) | completed | Phase 1 / Phase 2 | 37 | University Hospital HeidelbergOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01833832 | Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02720484 | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | terminated | Phase 2 | 10 | Northwestern UniversityOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00453895 | Sunitinib in Refractory Adrenocortical Carcinoma(SIRAC) | completed | Phase 2 | 39 | University of WuerzburgOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT00003453 | Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | terminated | Phase 2 | 6 | Burzynski Research InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT03257891 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines(CabACC) | unknown | Phase 2 | 25 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03145285 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma(ABACUS) | unknown | Phase 2 | 10 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01514526 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | completed | Phase 2 | 17 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | withdrawn | Phase 2 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00831844 | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 3 | Mar 30, 2015 | clinicaltrials |
| NCT00848016 | Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00778817 | IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | completed | Phase 2 | 30 | Ottawa Regional Cancer CentreOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00002921 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery | terminated | Phase 2 | 13 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00324012 | Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma | completed | Phase 2 | 19 | Rigshospitalet, DenmarkOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00454103 | Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy | completed | Phase 1 / Phase 2 | — | University of WuerzburgOTHER | 1 | Aug 18, 2010 | clinicaltrials |
| NCT00786110 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients(PAXO) | unknown | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Feb 24, 2009 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials